Glucosamine and Chondroitin for Knee Osteoarthritis: What 20 Years of Trials Show
Glucosamine is one of the most-bought supplements in the world and one of the most argued-over. The trials do not disagree at random: they split by which product was tested and who paid. Read that way, the evidence tells a clear story.
Evidence strength
Level 1a
Systematic review of RCTs
Peer-reviewed refs
19
Reading time
11 min
Key Takeaways
- The trials split by product. Crystalline glucosamine sulfate trials pooled to an effect size of −1.07; other glucosamine products pooled to −0.11, which is no effect. Brand explained 41% of the variation between trials.
- Who paid matters. Pooling individual patients from the industry-independent trials, 1,625 people, glucosamine was no better than placebo at 3 or 24 months in any subgroup.
- Pharmaceutical-grade chondroitin 800 mg beat placebo in a 604-person trial, 42.6 mm against 33.3 mm of pain reduction on a 100 mm scale, and matched celecoxib. Placebo alone moved pain by a third.
- The NIH GAIT trial in 1,583 people found no arm better than placebo except celecoxib, against a 60.1% placebo response. Glucosamine plus chondroitin did worse than placebo in a 164-person trial.
- Guidelines disagree. The American College of Rheumatology strongly recommends against both for knee osteoarthritis; the European society ESCEO recommends the prescription forms. Both put exercise and weight loss first.
- Our grade: C. If you try one, choose a defined product, run it alone for 12 weeks against a pain score you recorded first, and stop if it has not helped.
Walk into any pharmacy and the joint shelf is mostly glucosamine and chondroitin. Ask a rheumatologist and you may hear that they do nothing. Ask a European osteoarthritis society and you will hear that the prescription versions belong in the first step of treatment. All three answers are drawing on the same thirty years of trials. The disagreement is not noise: it follows two fault lines in the data, which product was tested and who paid for the trial. Once you sort the evidence along those lines, it stops looking contradictory.
What the Trials Actually Measured
Knee osteoarthritis trials measure two things: symptoms, usually pain and function on the WOMAC questionnaire or a 100 mm scale, and structure, the gap between the bones on an X-ray. Here is the evidence in rough order of trial size and independence.
| Trial or review | Who and how many | What they took | What changed |
|---|---|---|---|
| GAIT (NIH-funded), 24 weeks | 1,583 people with knee pain | Glucosamine HCl 1,500 mg, chondroitin 1,200 mg, both, celecoxib 200 mg, or placebo | Only celecoxib beat placebo; placebo response 60.1% |
| Independent-trial patient pool | 1,625 people, 5 trials | Glucosamine vs placebo | No effect at 3 or 24 months, in any subgroup |
| Crystalline sulfate, 3 years | 212 people | Glucosamine sulfate 1,500 mg | Joint-space loss −0.06 mm vs −0.31 mm on placebo |
| Crystalline sulfate, 3 years | 202 people | Glucosamine sulfate 1,500 mg | Joint-space +0.04 mm vs −0.19 mm; symptoms 20–25% better |
| CONCEPT, 6 months | 604 people | Pharmaceutical-grade chondroitin 800 mg | Pain −42.6 mm vs −33.3 mm on placebo; matched celecoxib |
| STOPP, 2 years | 622 people | Chondroitin 800 mg | Joint-space loss −0.07 mm vs −0.31 mm |
The NIH-funded GAIT trial is the largest and the only one designed to answer the question independently. Response rates on glucosamine were 3.9 percentage points better than placebo (P=0.30), chondroitin 5.3 points (P=0.17), the combination 6.5 points (P=0.09); celecoxib managed 10.0 points (P=0.008). [1] In a subgroup with moderate-to-severe pain the combination looked better, 79.2% against 54.3%, but that analysis was exploratory and has not been confirmed. We break the trial down in The 1,583-Person NIH Trial That Tested Glucosamine Against Celecoxib.
The positive glucosamine trials tested one product, a crystalline glucosamine sulfate, and scientists from its manufacturer were among the authors. Over three years they found joint-space narrowing almost stopped: −0.06 mm against −0.31 mm in one trial, +0.04 mm against −0.19 mm in the other, with symptoms 20–25% better. [2] [3] A six-month trial in 318 people found the same product beat placebo on the Lequesne index (−3.1 against −1.9) while acetaminophen, the side comparator, did not. [4]
Chondroitin's best trials also tested defined pharmaceutical products. In CONCEPT, 800 mg a day cut pain by 42.6 mm on a 100 mm scale against 33.3 mm on placebo, and matched celecoxib at 39.5 mm. [10] In STOPP, two years of 800 mg slowed joint-space loss to −0.07 mm against −0.31 mm, and 28% against 41% of participants progressed meaningfully. [11] The Cochrane review of 43 chondroitin trials found pain under six months 10 percentage points better than control on low-quality evidence, and a 20% improvement in function in 53 of 100 people against 47 of 100 on high-quality evidence. [9]
Where the Evidence Breaks Down
Brand explains much of it. A 2014 meta-analysis of 25 glucosamine trials found the overall effect size was −0.51, but with heterogeneity of 88%. Brand explained 41% of that heterogeneity. Trials of the crystalline sulfate product pooled to −1.07; every other product pooled to −0.11, with a confidence interval spanning zero. And within the crystalline sulfate trials, the three at low risk of bias gave −0.27. [5] The 2005 Cochrane review reached the same split: −1.31 for the one preparation, −0.15 and non-significant for the rest, and no benefit in the eight trials with adequate allocation concealment. [6]
Funding explains the rest. A network meta-analysis of 3,803 patients found pain differences against placebo of −0.4 cm for glucosamine, −0.3 cm for chondroitin and −0.5 cm for the combination on a 10 cm scale, all under the −0.9 cm the authors set as clinically important, and smaller in industry-independent trials. [8] An individual-patient analysis of the independent trials found glucosamine no better than placebo at any time point in any subgroup, and noted that industry trial data had not been shared with the trial bank. [7]
The combination is the weakest of all. In a six-month trial of 164 people, chondroitin 1,200 mg with glucosamine sulfate 1,500 mg reduced pain by 19%, against 33% on placebo: worse than doing nothing in the intention-to-treat analysis. [12] In a two-year trial of 605 people, the pair slowed joint-space narrowing by 0.10 mm with no pain benefit over placebo, and neither compound alone had any structural effect. [13] The 606-person trial that found the combination matched celecoxib had no placebo arm. [14]
Hips are not knees. Two years of crystalline glucosamine sulfate in 222 people with hip osteoarthritis made no difference to pain or joint space. [15]
Why the Placebo Arm Decides Everything
Osteoarthritis pain responds unusually well to placebo. A meta-analysis of 198 trials put the placebo effect on pain at an effect size of 0.51, against 0.03 for no treatment, and found it was larger in trials with higher baseline pain and stronger active comparators. [18] That is why GAIT's 60.1% placebo response matters, and why CONCEPT's placebo arm improved pain by a third. A supplement that does nothing will still make most people feel better for a while. Any trial without a placebo arm, and any personal experiment without a baseline score, will mistake that for an effect.
The same caution applies to the large UK Biobank cohorts that link habitual glucosamine use with lower all-cause mortality, hazard ratio 0.85. [19] People who take supplements differ from people who do not in ways no adjustment captures. It is not evidence that glucosamine helps your knee or your lifespan.
What the Guidelines Concluded
The 2019 American College of Rheumatology and Arthritis Foundation guideline strongly recommends against glucosamine for knee, hip and hand osteoarthritis, and against chondroitin and glucosamine-chondroitin combinations for knee and hip. It acknowledges that pharmaceutical-grade glucosamine was studied in several trials, then points to the gap between industry-sponsored and publicly funded results and the lack of benefit in the lowest-bias data. It conditionally recommends chondroitin for hand osteoarthritis. [16] The 2014 algorithm from the European society ESCEO takes the other side: prescription crystalline glucosamine sulfate and pharmaceutical-grade chondroitin sit in step one of knee osteoarthritis treatment. [17] Both put the same foundation underneath: exercise, weight loss and education.
Our Read: Grade C
We grade glucosamine and chondroitin C for knee osteoarthritis pain, and we grade the over-the-counter combination products lower. Supplement-aisle glucosamine hydrochloride is the form with the null NIH trial behind it. The crystalline sulfate and pharmaceutical-grade chondroitin have positive trials, but those trials come largely from one side of a funding divide that the independent evidence has not bridged. The structural results are fractions of a millimetre over years, and the two-year trial that found a structural effect from the combination found no pain benefit alongside it.
What would change the grade: an industry-independent, placebo-controlled trial of crystalline glucosamine sulfate or pharmaceutical-grade chondroitin reproducing the pain result. Until then the honest summary is that the best case for either compound is a small effect that may be real for specific products.
What This Means If You Are Deciding Now
Start with what works regardless of which guideline you read: strengthening exercise, weight loss if you carry extra weight, and topical NSAIDs for flares. If you still want to try a supplement, the trial data point to one product at a time for 12 weeks: crystalline glucosamine sulfate 1,500 mg once daily, or pharmaceutical-grade chondroitin 800 mg. Score your pain and function before you start so you can tell your result apart from the placebo response, and stop at 12 weeks if nothing has changed.
The short-term pain evidence for turmeric extracts is stronger than for either compound, with its own caveats, and the newer option, undenatured type II collagen, has one positive trial run by its supplier. How to sequence them, and when to stop, is set out in the Knee Osteoarthritis Supplement Trial. If you take warfarin, talk to your prescriber before starting either compound: raised INR has been reported with both.
Scientific References
- [1]Clegg DO, Reda DJ, Harris CL, et al.. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis — The New England Journal of Medicine (2006)Oxford 1bPMID 16495392
- [2]Reginster JY, Deroisy R, Rovati LC, et al.. Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial — Lancet (2001)Oxford 1bPMID 11214126
- [3]Pavelká K, Gatterová J, Olejarová M, et al.. Glucosamine sulfate use and delay of progression of knee osteoarthritis: a 3-year, randomized, placebo-controlled, double-blind study — Archives of Internal Medicine (2002)Oxford 1bPMID 12374520
- [4]Herrero-Beaumont G, Ivorra JA, Del Carmen Trabado M, et al.. Glucosamine sulfate in the treatment of knee osteoarthritis symptoms: a randomized, double-blind, placebo-controlled study using acetaminophen as a side comparator — Arthritis and Rheumatism (2007)Oxford 1bPMID 17265490
- [5]Eriksen P, Bartels EM, Altman RD, et al.. Risk of bias and brand explain the observed inconsistency in trials on glucosamine for symptomatic relief of osteoarthritis: a meta-analysis of placebo-controlled trials — Arthritis Care & Research (2014)Oxford 1aPMID 24905534
- [6]Towheed TE, Maxwell L, Anastassiades TP, et al.. Glucosamine therapy for treating osteoarthritis — The Cochrane Database of Systematic Reviews (2005)Oxford 1aPMID 15846645
- [7]Runhaar J, Rozendaal RM, van Middelkoop M, et al.. Subgroup analyses of the effectiveness of oral glucosamine for knee and hip osteoarthritis: a systematic review and individual patient data meta-analysis from the OA trial bank — Annals of the Rheumatic Diseases (2017)Oxford 1aPMID 28754801
- [8]Wandel S, Jüni P, Tendal B, et al.. Effects of glucosamine, chondroitin, or placebo in patients with osteoarthritis of hip or knee: network meta-analysis — BMJ (2010)Oxford 1aPMID 20847017
- [9]Singh JA, Noorbaloochi S, MacDonald R, et al.. Chondroitin for osteoarthritis — The Cochrane Database of Systematic Reviews (2015)Oxford 1aPMID 25629804
- [10]Reginster JY, Dudler J, Blicharski T, et al.. Pharmaceutical-grade Chondroitin sulfate is as effective as celecoxib and superior to placebo in symptomatic knee osteoarthritis: the ChONdroitin versus CElecoxib versus Placebo Trial (CONCEPT) — Annals of the Rheumatic Diseases (2017)Oxford 1bPMID 28533290
- [11]Kahan A, Uebelhart D, De Vathaire F, et al.. Long-term effects of chondroitins 4 and 6 sulfate on knee osteoarthritis: the study on osteoarthritis progression prevention, a two-year, randomized, double-blind, placebo-controlled trial — Arthritis and Rheumatism (2009)Oxford 1bPMID 19180484
- [12]Roman-Blas JA, Castañeda S, Sánchez-Pernaute O, et al.. Combined Treatment With Chondroitin Sulfate and Glucosamine Sulfate Shows No Superiority Over Placebo for Reduction of Joint Pain and Functional Impairment in Patients With Knee Osteoarthritis — Arthritis & Rheumatology (2017)Oxford 1bPMID 27477804
- [13]Fransen M, Agaliotis M, Nairn L, et al.. Glucosamine and chondroitin for knee osteoarthritis: a double-blind randomised placebo-controlled clinical trial evaluating single and combination regimens — Annals of the Rheumatic Diseases (2015)Oxford 1bPMID 24395557
- [14]Hochberg MC, Martel-Pelletier J, Monfort J, et al.. Combined chondroitin sulfate and glucosamine for painful knee osteoarthritis: a multicentre, randomised, double-blind, non-inferiority trial versus celecoxib — Annals of the Rheumatic Diseases (2016)Oxford 1bPMID 25589511
- [15]Rozendaal RM, Koes BW, van Osch GJ, et al.. Effect of glucosamine sulfate on hip osteoarthritis: a randomized trial — Annals of Internal Medicine (2008)Oxford 1bPMID 18283204
- [16]Kolasinski SL, Neogi T, Hochberg MC, et al.. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee — Arthritis & Rheumatology (2020)Oxford 1aPMID 31908163
- [17]Bruyère O, Cooper C, Pelletier JP, et al.. An algorithm recommendation for the management of knee osteoarthritis in Europe and internationally: a report from a task force of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) — Seminars in Arthritis and Rheumatism (2014)Oxford 5PMID 24953861
- [18]Zhang W, Robertson J, Jones AC, et al.. The placebo effect and its determinants in osteoarthritis: meta-analysis of randomised controlled trials — Annals of the Rheumatic Diseases (2008)Oxford 1aPMID 18541604
- [19]Li ZH, Gao X, Chung VC, et al.. Associations of regular glucosamine use with all-cause and cause-specific mortality: a large prospective cohort study — Annals of the Rheumatic Diseases (2020)Oxford 2bPMID 32253185
Follow us on Google Search
Add BiohackingHub as a preferred source to see more of our research in Google results.
Related protocols
Partner with BiohackingHub
Editorial placements, sponsorships, and product features for evidence-minded brands.